Novel treatments for inflammatory bowel diseaseopen access
- Authors
- Lee, H.S.[Lee, H.S.]; Park, S.-K.[Park, S.-K.]; Park, D.I.[Park, D.I.]
- Issue Date
- Jan-2018
- Publisher
- Korean Association of Internal Medicine
- Keywords
- Inflammatory bowel diseases; Janus kinase inhibitors; Anti-mucosal vascular addressin cell adhesion molecule-1 agent; Anti-SMAD7 antisense oligonucleotide; Anti-interleukin-12/23
- Citation
- Korean Journal of Internal Medicine, v.33, no.1, pp.20 - 27
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Korean Journal of Internal Medicine
- Volume
- 33
- Number
- 1
- Start Page
- 20
- End Page
- 27
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/25730
- DOI
- 10.3904/kjim.2017.393
- ISSN
- 1226-3303
- Abstract
- Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has led to the development of targeted therapies and has unlocked a new era in IBD treatment. The development of treatment options aimed at a variety of pathological mechanisms offers new hope for customized therapies. Beyond anti-tumor necrosis factor agents, selective lymphocyte trafficking inhibitors have been proposed as potent drugs for IBD. Among these, vedolizumab has recently been approved for both Crohn’s disease and ulcerative colitis. Numerous other agents for IBD treatment are currently under investigation, including Janus kinase inhibitors, anti-mucosal vascular addressin cell adhesion molecule-1 agents, an anti-SMAD7 antisense oligonucleotide, an anti-interleukin-12/23 monoclonal antibody, and a sphingosine-1-phosphate receptor-1 selective agonist. These agents will likely expand the treatment options available for the management of IBD patients in the future. In this review, we discuss the efficacy and safety of novel agents currently under investigation in IBD clinical trials. © 2018 The Korean Association of Internal Medicine.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.